Apalutamide Elicits PSA Response, Lowers Progression to Castration Resistant Disease in mCSPC
April 30th 2023Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.
Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC
September 23rd 2021Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.